Magnesium and Dexmedetomidine in Pheochromocytoma

Magnesium and Dexmedetomidine Combination Reduces Sodium Nitroprusside Requirement in Laparoscopic Pheochromocytoma

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05102058

Enrollment

108

Registered

2021-11-01

Start date

2011-01-01

Completion date

2020-03-01

Last updated

2021-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodynamic Instability, Phaeochromocytoma Crisis

Keywords

Magnesium, Dexmedetomidine, Nitroprusside, Pheochromocytoma

Brief summary

Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration between the group treated with magnesium-dexmedetomidine and conventional group in pheochromocytoma.

Interventions

DRUGMagnesium-Dexmedetomidine

Received oral 300 mg magnesium one week before surgery and magnesium-dexmedetomidine combination perioperatively

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* American Society of Anesthesiologists classification (ASA) 1-3 * high urinary catecholamine or metabolites * tumor sizes \< 5 cm * body mass index (BMI) \<35 kg/m2

Exclusion criteria

* open surgery * bilateral masses * tumor larger than 5 cm * incomplete data

Design outcomes

Primary

Measure	Time frame	Description
Sodium nitroprusside (SNP) requirement	intraoperative period	intraoperative hypertensive episodes requiring SNP therapy

Secondary

Measure	Time frame	Description
vasoactive therapy	intraoperative period	hemodynamic fluctuations (hypotension, tachycardia, severe hypertensive crisis) which needed vasoactive therapy.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026